Roundup of Antibody Biotech Deals in February 2026

February 2026 activity showcased investment in CNS-targeting antibodies, advanced delivery technologies, and next-generation formats such as antibody-oligo conjugates and recombinant polyclonal IgGs. Large-scale strategic collaborations and sustained financing remained for platform-driven innovation, particularly between AI and biologics discovery. 

🔍 February Deal Signals

• Increased focus on CNS-targeting antibodies, particularly for neurodegenerative diseases 
  

• Continued rise of advanced delivery technologies, including antibody-oligo conjugates 
  

• Strong presence of large-scale strategic collaborations, with multi-billion-dollar potential 
  

• AI-driven discovery and analytics further embedded across antibody R&D workflows 
  

• Early-stage and platform companies continue to attract substantial Series A/B financing 

🤝 Strategic Collaborations & Research Partnerships

• Innovent Biologics × Eli Lilly – Strategic collaboration to develop new oncology and immunology medicines globally, with potential deal value of up to $8.5B.

• Memo Therapeutics × CSL – Collaboration and option agreement to develop recombinant polyclonal IgG technology, valued at up to $328M.

• BostonGene × Daiichi Sankyo – Strategic collaboration to accelerate ADC development using AI-driven multimodal analytics.

• Nektar Therapeutics × University of California, San Francisco – Research collaboration to advance NKTR-0165, a TNFR2 antibody, for multiple sclerosis.

💵 Licensing & Option Deals 

• Solstice Oncology × Harbour BioMed – Exclusive worldwide license for porustobart, an anti-CTLA-4 antibody, with total deal value up to $1.2B.

• Eli Lilly and Company × CSL Limited – $100M upfront payment for clazakizumab, an anti-IL-6 monoclonal antibody.

💸 Financings & Company Launches

• Korsana Biosciences – Emerged from stealth with $175M to advance next-generation shuttled monoclonal antibodies targeting amyloid beta for neurodegenerative diseases. 

• Slate Medicines – Launched with $130M Series A to develop an anti-PACAP monoclonal antibody for migraine and headache disorders. 

• Third Arc Bio – Raised $52M Series A extension to expand its multifunctional antibody portfolio in oncology and immunology & inflammation. 

• Aerska – Raised $39M Series A to advance an antibody-oligo conjugate (AOC) platform for systemic RNA delivery to the brain. 

• Galux – Secured $29M Series B to advance AI-driven de novo protein design for antibody therapeutics. 

• Kainova Therapeutics – Raised $32M CAD to support development of immuno-oncology and inflammation therapies, including a Treg-depleting anti-CCR8 antibody.